Tag Archives: Alabama Defense Lawyer

Cabozantinib Granted FDA Approval for Advanced HCC – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF Cabozantinib Granted FDA Approval for Advanced HCC – APhA submits compounding comments to FDA. – (866) 348-2889. The FDA has approved cabozantinib (Cabometyx, Exelixis) as a treatment for patients with hepatocellular … Continue reading

Posted in Pharmacist | Tagged , , , | Leave a comment

National Pharmacist Day Elicits Pride for the Profession – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF National Pharmacist Day Elicits Pride for the Profession – APhA submits compounding comments to FDA. – (866) 348-2889. On National Pharmacist Day, public awareness is generated for everything these health care … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

Vulvodynia Study Endorsing Gabapentin for Pelvic Muscle Pain: An In-depth Look – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF Vulvodynia Study Endorsing Gabapentin for Pelvic Muscle Pain: An In-depth Look – APhA submits compounding comments to FDA. – (866) 348-2889. Sexual pain in women remains a difficult and elusive medical … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

Viral Decision-Making Factors in Latent HIV Reservoirs Identified in Study – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF Viral Decision-Making Factors in Latent HIV Reservoirs Identified in Study – APhA submits compounding comments to FDA. – (866) 348-2889. Research efforts have targeted latent HIV reservoirs as a potential way … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

Breakthrough Therapy Designation Granted for Sickle Cell Disease Treatment – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF Breakthrough Therapy Designation Granted for Sickle Cell Disease Treatment – APhA submits compounding comments to FDA. – (866) 348-2889. Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

FDA Authorizes Generic Lurasidone Hydrochloride Tablets – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF FDA Authorizes Generic Lurasidone Hydrochloride Tablets – APhA submits compounding comments to FDA. – (866) 348-2889. The FDA has approved marketing of Lupin Pharmaceuticals’ Lurasidone Hydrochloride Tablets, a generic version of … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

FDA approved a record number of drugs in 2018 – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF FDA approved a record number of drugs in 2018 – APhA submits compounding comments to FDA. – (866) 348-2889. FDA drug approvals hit an all-time high in 2018, with 59 new … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

Dasatinib Approved for Treatment of Certain Pediatric Patients – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF Dasatinib Approved for Treatment of Certain Pediatric Patients – APhA submits compounding comments to FDA. – (866) 348-2889. The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

Study: Genetic Risk Variant Linked to Astrocytes Increases Risk of MS – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF Study: Genetic Risk Variant Linked to Astrocytes Increases Risk of MS – APhA submits compounding comments to FDA. – (866) 348-2889. A genetic risk variant, rs7665090G, located near NFKB1, on astrocytes enhances … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off

IDSA Updates Guidelines on Flu Diagnosis and Response – APhA submits compounding comments to FDA.

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF IDSA Updates Guidelines on Flu Diagnosis and Response – APhA submits compounding comments to FDA. – (866) 348-2889. Outpatients who have been diagnosed with influenza and are at high risk for … Continue reading

Posted in Pharmacist | Tagged , , , | Comments Off